NYSE:AVNS

Avanos Medical Stock Forecast, Price & News

$32.49
+0.71 (+2.23 %)
(As of 09/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$31.65
$32.58
50-Day Range
$31.38
$38.50
52-Week Range
$30.96
$53.61
Volume359,379 shs
Average Volume362,872 shs
Market Capitalization$1.56 billion
P/E Ratio1,083.00
Dividend YieldN/A
Beta0.91
30 days | 90 days | 365 days | Advanced Chart
Receive AVNS News and Ratings via Email

Sign-up to receive the latest news and ratings for Avanos Medical and its competitors with MarketBeat's FREE daily newsletter.


Avanos Medical logo

About Avanos Medical

Avanos Medical, Inc. operates as a medical technology company. It focuses on delivering clinically medical device solutions to improve patients' quality of life. The firm's portfolio of product offerings focuses on respiratory and digestive health, along with surgical and interventional pain management to improve patient outcomes and reduce the cost of care. Its brands include ON-Q, Coolife, Microcuff, MIC-Key, Quilbloc and Home pump. The company was founded on February 25, 2014 and is headquartered in Alpharetta, GA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.44 out of 5 stars

Medical Sector

446th out of 1,352 stocks

Surgical Appliances & Supplies Industry

13th out of 26 stocks

Analyst Opinion: 3.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Avanos Medical (NYSE:AVNS) Frequently Asked Questions

Is Avanos Medical a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Avanos Medical in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" Avanos Medical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVNS, but not buy additional shares or sell existing shares.
View analyst ratings for Avanos Medical
or view top-rated stocks.

What stocks does MarketBeat like better than Avanos Medical?

Wall Street analysts have given Avanos Medical a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Avanos Medical wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Avanos Medical's next earnings date?

Avanos Medical is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for Avanos Medical
.

How were Avanos Medical's earnings last quarter?

Avanos Medical, Inc. (NYSE:AVNS) released its quarterly earnings data on Monday, August, 2nd. The company reported $0.21 earnings per share for the quarter, missing the Zacks' consensus estimate of $0.23 by $0.02. The business earned $186.40 million during the quarter, compared to analyst estimates of $180.56 million. Avanos Medical had a net margin of 0.33% and a trailing twelve-month return on equity of 3.52%. The firm's revenue for the quarter was up 13.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.13 earnings per share.
View Avanos Medical's earnings history
.

How has Avanos Medical's stock price been impacted by Coronavirus (COVID-19)?

Avanos Medical's stock was trading at $29.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AVNS shares have increased by 12.0% and is now trading at $32.49.
View which stocks have been most impacted by COVID-19
.

What guidance has Avanos Medical issued on next quarter's earnings?

Avanos Medical issued an update on its FY 2021 earnings guidance on Tuesday, August, 10th. The company provided earnings per share (EPS) guidance of $1.100-$1.200 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.210. The company issued revenue guidance of $729.10 million-$743.39 million, compared to the consensus revenue estimate of $741.22 million.

What price target have analysts set for AVNS?

3 equities research analysts have issued 12 month target prices for Avanos Medical's stock. Their forecasts range from $41.00 to $47.00. On average, they anticipate Avanos Medical's share price to reach $44.33 in the next twelve months. This suggests a possible upside of 36.5% from the stock's current price.
View analysts' price targets for Avanos Medical
or view top-rated stocks among Wall Street analysts.

Who are Avanos Medical's key executives?

Avanos Medical's management team includes the following people:
  • Joseph F. Woody, Chief Executive Officer & Executive Director
  • Michael C. Greiner, Chief Financial Officer & Senior Vice President
  • Lee Burnes, Senior VP-Global Research & Development
  • Michelle Scharfenberg, Senior VP, Chief Ethics & Compliance Officer
  • Rhonda D. Gibby, Chief Human Resources Officer & Senior VP

What is Joseph F. Woody's approval rating as Avanos Medical's CEO?

32 employees have rated Avanos Medical CEO Joseph F. Woody on Glassdoor.com. Joseph F. Woody has an approval rating of 51% among Avanos Medical's employees. This puts Joseph F. Woody in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Avanos Medical's key competitors?

What other stocks do shareholders of Avanos Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avanos Medical investors own include Kimberly-Clark (KMB), CVS Health (CVS), Honeywell International (HON), Pfizer (PFE), The Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), AT&T (T), Abbott Laboratories (ABT) and Alibaba Group (BABA).

What is Avanos Medical's stock symbol?

Avanos Medical trades on the New York Stock Exchange (NYSE) under the ticker symbol "AVNS."

Who are Avanos Medical's major shareholders?

Avanos Medical's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (15.32%), Vanguard Group Inc. (10.59%), Champlain Investment Partners LLC (5.42%), Price T Rowe Associates Inc. MD (5.14%), Dimensional Fund Advisors LP (4.95%) and RGM Capital LLC (4.48%). Company insiders that own Avanos Medical stock include Gary Blackford and Patrick J Oleary.
View institutional ownership trends for Avanos Medical
.

Which institutional investors are selling Avanos Medical stock?

AVNS stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Price T Rowe Associates Inc. MD, Champlain Investment Partners LLC, JPMorgan Chase & Co., Northern Trust Corp, Tygh Capital Management Inc., William Blair Investment Management LLC, and Employees Retirement System of Texas.
View insider buying and selling activity for Avanos Medical
or view top insider-selling stocks.

Which institutional investors are buying Avanos Medical stock?

AVNS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Morgan Stanley, Morgan Stanley, Nuveen Asset Management LLC, RGM Capital LLC, Principal Financial Group Inc., and Macquarie Group Ltd.. Company insiders that have bought Avanos Medical stock in the last two years include Gary Blackford, and Patrick J Oleary.
View insider buying and selling activity for Avanos Medical
or or view top insider-buying stocks.

How do I buy shares of Avanos Medical?

Shares of AVNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avanos Medical's stock price today?

One share of AVNS stock can currently be purchased for approximately $32.49.

How much money does Avanos Medical make?

Avanos Medical has a market capitalization of $1.56 billion and generates $714.80 million in revenue each year. The company earns $-27,200,000.00 in net income (profit) each year or $0.79 on an earnings per share basis.

How many employees does Avanos Medical have?

Avanos Medical employs 5,300 workers across the globe.

What is Avanos Medical's official website?

The official website for Avanos Medical is avanos.com.

Where are Avanos Medical's headquarters?

Avanos Medical is headquartered at 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004.

How can I contact Avanos Medical?

Avanos Medical's mailing address is 5405 Windward Parkway Suite 100 South, Alpharetta GA, 30004. The company can be reached via phone at (844) 428-2667 or via email at [email protected]


This page was last updated on 9/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.